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INTRODUCTION
The kidney and the skin are the two large networks of the body with their abundant 
blood supply, far in excess of their nutritional demands, the former for the constancy of the 
milieu interior and the latter maintaining mainly homeostasis. No wonder therefore, that they 
share many diseases and reflect mutually one another’s pathology which should be made use 
of by the clinician. Scientific and technologic improvements during the second-half of the 20th 
century  have  provided  renal  replacement  therapy  as  a  life-sustaining  option  for  many 
individuals who otherwise may have died. For each year of the last 10 years, the number of 
individuals with end stage renal disease has grown approximately 20,000 per year.
Cutaneous examination of patients with end stage renal disease has shown that 50 – 
100% of the patients have at least one dermatologic condition. In addition to end stage renal 
disease,  Uremia  and  conditions  associated  with  replacement  therapy  are  fraught  with 
numerous and, often relatively unique cutaneous disorders.
REVIEW OF LITERATURE
DEFINITION:
Chronic  renal  failure  is  defined  as  the  irreversible,  substantial  and  usually  long-
standing loss of renal function causing ill health usually referred to as uremia.
End  stage  renal  disease  represents  a  clinical  state  in  which  there  has  been  an 
irreversible loss of  endogenous renal  function of  a degree sufficient to render the patient 
permanently dependent upon renal replacement therapy (dialysis or renal transplantation) in 
order to avoid life-threatening uremia1. Uremia  is  the  clinical  and  laboratory  syndrome 
reflecting dysfunction of all organ systems as a result of untreated or under treated acute or 
chronic renal failure.1
PREVALENCE AND INCIDENCE:
The true prevalence of chronic renal failure is unknown because many patients are 
asymptomatic or its presence has not been recognized. The prevalence of end-stage renal 
disease will  vary from country to country and will  depend upon the incidence of particular 
disease and the availability and capacity of dialysis and transplant programs.
There are real differences in the incidence of end-stage renal disease according to 
age, gender and race. In western countries the incidence is lowest in children and highest in 
the elderly between 30 and 60 years and is slightly higher in males than females 2. The higher 
prevalence in developing countries may be due to higher incidence of infections leading on to 
as well as genetic and environmental predisposition, and socio-economic factors and access 
to medical care 2
ETIOLOGY:
Chronic  renal  failure  may be caused  by any condition,  which  destroys  the  normal 
structure and function of the kidney. There are many causes of chronic renal failure, for most 
renal diseases can eventually lead to a significant reduction in function 3
Review of the 2001 report revealed diabetes mellitus to be the most common cause of 
end stage renal disease from 1993 – 97.  Diabetes mellitus was responsible for more than 
44% of new cases 2.
Etiology of chronic renal failure 3
A) Congenital and inherited diseases
• Polycystic kidney disease
• Alports syndrome 
• Congenital hypoplasia
B) Vascular diseases
• Arteriosclerosis (Hypertension)
• Vasculitis (Poly arteritis nodosa, Systemic lupus erythematosus, 
Scleroderma)
C) Glomerular diseases
• Proliferative Glomerulonephritis
• Crescentic Glomerulonephritis
• Membranous Glomerulonephritis
• Mesangiocapillary Glomerulonephritis
• Glomerulosclerosis
• Diabetic glomerulosclerosis
• Secondary Glomerulonephritis (Poly arteritis nodosa, Systemic lupus 
erythematosus, Amyloidosis)
D) Interstitial diseases
• Chronic pyelonephritis
• Vesico ureteric reflux
• Tuberculosis
• Analgesic nephropathy
• Nephrocalcinosis
• Schistosomiasis
• Unknown origin
E) Obstructive uropathy
• Calculus
• Retroperitoneal fibrosis
• Prostatic hypertrophy
• Pelvic tumors
F) Rare causes < 1% of the cases
• Alport’s syndrome
• Hemolytic uremic syndrome
• Metabolic disorders
PATHOPHYSIOLOGY OF CHRONIC RENAL FAILURE: 4, 6
The  exact  pathogenesis  of  the  clinical  syndrome  of  uremia  is  unknown.  The 
pathophysiology of uremic syndrome is attributable to accumulation of products of protein 
metabolism and loss of other renal functions such as fluid and electrolyte homeostasis and 
synthesis of certain hormones (1, 25 – dihydroxy cholecalciferol) 7. The various uremic toxins 5 
are by-products of protein and aminoacid metabolism such as urea, guanido compounds, 
methyl guanidines, urates, hippurates, 
end - products of nucleic acid metabolism, end products of aliphatic acid metabolism, end- 
products of aromatic amino acid metabolism and other nitrogenous substances, inhibitors of 
ligand protein binding, glucurono conjugates and inhibitors of somatomedin and insulin action. 
The pathophysiology has been explained based on two hypotheses. They are as follows: 
1. Intact nephron hypothesis:- that is most nephrons are non-functioning, while the remaining 
few function normally.
2. Trade off hypothesis:- It is the concept that adaptations arising in chronic renal failure may 
control one abnormality, but only in such a way as to produce other changes characteristic 
of uremic syndrome. The best example of “trade off” is increase of parathormone secretion 
essential for increased fractional excretion of phosphate.
When  kidney  function  is  entirely  normal,  glomerular  filtration  rate  (GFR)  can  be 
augmented by 20 – 30% in response to the stimulus of  a protein challenge. As GFR 
declines to levels as low as 30% of normal, patients may remain asymptomatic with only 
biochemical evidence of the decline in GFR. As GFR falls to below 30% of normal, an 
increasing  number  and  severity  of  uremic  clinical  manifestations  and  biochemical 
abnormalities supervene. When GFR falls below 5 – 10% of normal, continued survival 
without renal replacement therapy becomes impossible 5.
CLINICAL PRESENTATION AND ASSESSMENT:
In the early stages of the disease the patient may be asymptomatic and the existence 
of renal insufficiency may be revealed incidentally. Subsequently because of the widespread 
effects of progressive renal failure, symptoms and signs are referable to almost every system. 
None of these symptoms alone is indicative of underlying renal disease, but the occurrence of 
more than one would suggest the possibility of renal failure.
Indications of chronicity of renal failure 2:
1. Symptoms: fatigue, breathlessness, anorexia, nausea, vomiting, hiccoughs, pruritus, 
dry skin, bone pain, nocturia, muscle cramps, drowsiness, seizures, amenorrhoea, decreased 
libido.
2.  Signs:  Pallor,  pigmentation,  increased  respiratory  rate,  hypertension,  increased 
jugular  venous  pulsation,  pedal  edema,  pulsus  paradoxus  (pericardial  tamponade), 
excoriations due to pruritus, brown nails, xerosis, paraesthesia, absent reflexes.
3.  Investigations:  Complete  hemogram  shows  normochromic  normocytic  anemia, 
increased  blood  urea  and  serum  creatinine,  serum  electrolytes  showing  hyperkalemia, 
hyperphosphatemia, hypocalcemia, hyponatremia and low serum bicarbonate, serum proteins 
showing  hypo  albuminemia,  urinalysis  shows  proteinuria,  total  24  hr  urine  collection  for 
estimating urinary proteins and creatinine clearance, urine sediment findings showing RBCs, 
RBC cast, WBC cast, blood sugar, hepatitis B & C viral detection, Blood VDRL, Anti nuclear 
anti-bodies,  double  stranded  
DNA, c – ANCA, p – ANCA, serum complements and imaging studies such as plain X – ray 
abdomen to detect radio-opaque stones or nephrocalcinosis, renal ultrasonogram showing 
small kidneys usually, CT – scan, MRI, radio nuclide scan, intravenous pyelogram, voiding 
cysto-urethrogram and renal biopsy.
SYSTEMIC EFFECTS OF UREMIA: 6
The effects of uremia are diverse and almost every system is affected. They include 
cardiovascular,  pulmonary,  hematologic,  neuromuscular,  gastrointestinal  abnormalities, 
endocrine and metabolic disturbances and the most clinching dermatologic abnormalities.
DERMATOLOGIC ABNORMALITIES: Reports indicate that 50 – 100% of patients with 
end-stage renal disease have at least one cutaneous
disorder 7 . The abnormalities affecting the skin may be manifested as
I. Specific cutaneous manifestations of chronic renal failure
II. Skin manifestations due to treatment (drugs & dialysis) of renal failure.
I. SPECIFIC CUTANEOUS MANIFESTATIONS OF CRF
Primary dermatologic manifestations associated with uremia are
A. SKIN CHANGES
          1. Pruritus:
 Uremia  is  the  most  common metabolic  cause of  pruritus  and pruritus  is  the  most 
common and troublesome cutaneous manifestation of uremia.
Incidence:
Significant pruritus affects 15 – 49% of patients with chronic renal failure. Pruritus more 
commonly begins approximately 6 months after initiation of dialysis and typically increases 
with the length of time on dialysis. It has no consistent association with age, sex, race or 
precipitating disease. Pruritus may be episodic or constant, localized or generalized and mild 
or severe. The axillae, scalp, nose and ears are the most frequent areas of pruritus. When 
localized, the forearms and upper back predominantly are affected 2. Pruritus often worsens 
at bedtime. Pruritus is not a feature of acute renal failure. For about 25% of the patients with 
pruritus, it occurs only during or soon after dialysis and it is more severe at these times for an 
additional 42% of the patients.8
Etiopathogenesis: 
Several  researches  have  concluded  that  end  stage  renal  disease  prutitus  is 
multifactorial.9, 10 Some proposed causes of uremic pruritus include the following:
• Xerosis – In a study by Kato (2000) 11,  the skin water content was quantified by using a 
hygrometer to determine the amount of high frequency conductance in the skin surface. 
Final analysis concluded that dialysis patients have less water content in their stratum 
corneum of their skin, but there was no association with pruritus severity.
• Decreased transepidermal elimination of pruritogenic factors
• Hyperparathyroidism  –  results  in  hypercalcemia  and  skin  calcifications  which  in  turn 
stimulates skin mast cells with consequent release of histamine.12
• Hyperphosphatemia
• Hypervitaminosis A13   -  elicit  xerotic and pruritic skin in uremic individuals not receiving 
dialysis. Certain patients have been shown to exhibit increased levels of retinol.14
• Increased dermal  mast  cell  proliferation  and elevated histamine levels  15 –  mast  cells 
proliferate in renal failure and are known to function as a storage and release site for 
histamine.  Mast  cell  histamine release plays  an important  role  in  the pathogenesis  of 
various allergic conditions. The mast cell proliferation theory was refuted when ultra violet 
light therapy was shown to decrease the number of mast cells without a corresponding 
decrease in pruritus.
• Increased serotonin levels 16
• Uremic  sensory  neuropathy  17–  Johannson,  Hlliges,  &  Stahle  –Backdahl  (1989)  18, 
identified and implicated a fine neuron specific immuno reactive nerve fiber laden with 
enolase, an acidic enzyme found in neurons, neuro endocrine cells and tumours derived 
from them. This discovery was considered the probable cause for end stage renal disease 
pruritus since the immuno histochemical stains that demonstrated these fibres were not 
evident in non-pruritic end stage renal disease patients.
• Middle molecule theory:  Suggests the retention of  unidentified pruritogenic substances 
that accumulate in the dialysis patient since they are poorly dialyzable as a result of their 
molecular  size of  300 – 12,000 daltons.  β2 microglobulin,  advanced glycosylation end 
products and parathyroid hormones are the middle molecules that have been evaluated, 
but their role is uncertain. 
Clinical presentation:
Normal or Xerotic skin
Excoriations from scratching
Prurigo nodularis
LSC
Treatment of pruritus:
i. Exclude other clinical causes such as scabies and other non-end stage renal disease 
causes of pruritus and treat it.
ii. Regular daily application of emollients alleviate xerosis by depleting the skin of prutitic 
agent.
iii. Augmentation of dialysis efficacy 15, 19
iv. Normalization of serum calcium and phosphate levels
v. Parathyroidectomy
vi. UVB therapy 20–may reduce the epidermal retinol content 14
PUVA –  reduction  in  dermal  histamine  21.  These form the  mainstay of  therapy  14. 
Reduction of skin phosphorous to normal values, possibly through an effect of Vitamin 
D.22
vii. In dialysis, lowering the Mg concentration of the dialysate 23.
viii.Cholestyramine (5g bd) 24 – it binds uric acid
ix. Oral activated charcoal 26  (6g daily x 8 weeks). By chelation in the gut of a circulating 
toxin 25.
x. Heparin infusion 27
xi. IV lidocaine 100mg – was effective in relieving uremic pruritus for up to 24 hrs in some 
patients 28. Topical anesthetics such as Pramoxine have been tried.
xii.Nicerogoline 30 mg orally Qid + 5 mg IV at dialysis for 2 weeks (dopamine agonist) 29
xiii.Ketotifen 1- 2 mg bd (mast cell stabilizer) 30
xiv.Trans-cutaneous electrical needle stimulation, a modified acupuncture technique 31  – 
lateral inhibition impulses halt itch.
xv.   Topical capsaicin 0.025%, an irritant cream that depletes      substance P in 
peripheral sensory neurons 32., thereby suppressing itch sensation.
xvi.Cimetidine 33
xvii.Erythropoietin – reduction of plasma histamine concentration 34
xviii.Opiate receptor antagonists – naloxone and naltrexone 35
xix.Mexiletine 35
xx. Oral evening primrose oil 36, 37 and topical Tacrolimus 36, 37
2. Xerosis / Ichthyosis:
Cutaneous dryness is  the most  frequent  cutaneous abnormality in uremic patients. 
Significant xerosis occurs for unknown reasons in 50 – 75% of the dialysis population. When 
xerosis  is associated with  desquamation it  can cause an ichthyosis-like appearance.  The 
extensor surfaces of legs and arms are most severely affected with large dark scales whereas 
over the abdomen the scales are whitish to translucent and somewhat smaller and finer. The 
scalp is frequently involved with pityriasic desquamation. The flexor surfaces, the axillae and 
the ante-cubital and the popliteal fossae are relatively spared. Some patients may develop 
acquired ichthyosis. Patients with dry skin may also show signs of abnormal keratinization or 
excessive  production  of  keratin  such as  follicular  keratosis,  onychodystrophy and  plantar 
hyperkeratosis. Sometimes variable degree of hyperkeratosis occur even without concomitant 
xerosis. Xerosis generally appears before initiation of dialysis therapy and seems to be little 
influenced by dialysis.38
Etiopathogenesis of xerosis:
The pathogenesis is poorly understood. Factors implicated are
i. Impairment of exocrine sweat gland with decreased sweating. 39, 40
ii. Decrease in water content in the epidermis.
iii. Hyper or hypovitaminosis A– plasma and skin content of vit.A and its carrier, retinol 
binding protein are increased in uremic patients. 38
iv. Increased plasma levels of parathormone with secondary hyperparathyroidism
v. Disorder in Vitamin D metabolism.
vi. Uremia induced alteration in corneocyte maturation.
Pathology:
A reduction in the size of eccrine glands as well as atrophy of sebaceous glands. 39
Electron microscopy:
Increased number of corneal cell layers with desmosomal junctions present up to the 
skin surface. Increased number of keratinosomes showing several degrees of alterations. 38
Treatment:
There  is  no  specific  treatment  for  uremic  xerosis  and  ichthyosiform  dermatosis. 
Emollients may give symptomatic relief.
3. Pigmentary alterations: A multitude of uremia related changes are responsible for 
the pigmentary alterations.
 Pallor – it was common before the widespread use of erythropoietin. It is attributed to 
the significant anemia (reduced erythropoiesis and increased hemolysis)
 Sallow yellow discolouration is attributed to retained urochromes and carotene in the 
epidermis and subcutaneous tissue2.
 Diffuse hyper pigmentation in sun exposed areas results from an increased deposition 
of  melanin  in  the  basal  layer  of  the  epidermis  and  superficial  dermis.  Due  to  an 
increase in poorly dialyzable β Melanocyte stimulating hormone,41,42 there is increased 
melanogenesis with resultant deposition of melanin.  
 An increased prevalence of hyper pigmented macules on the palms and soles has 
been reported in a large series of uremic patients.43
4. Uremic frost:
First described by Hirschprung in 1865, uremic frost 38 is rarely seen today because of 
early dialytic intervention.
It is a classic manifestation of CRF consisting of white deposits on the skin of the face, 
commonly on beard area, neck and trunk. It dissolves readily when challenged by a drop of 
water. 
Pathogenesis:
When the blood urea nitrogen level is adequately high (usually >250-300 mg/dl), the 
concentration of urea in sweat is increased greatly. Evaporation results in the deposition of 
urea crystals on the skin. 42
5. Perforating disorders:
4 –  10%  63  of  patients  with  chronic  renal  failure  develop  various  perforating 
disorders. They may present as four primary perforating disorders
i. Kyrle’s disease
ii. Perforating folliculitis
iii. Reactive perforating collagenosis
iv. Elastosis perforans serpiginosa or as 
v. Perforating disorder secondary to uremic follicular hyperkeratosis
Pathogenesis: Etiology unclear. Proposed to be 
• Local trauma (scratching)
• Dermal  micro  deposition  of  substances  such  as  uric  acid  and  calcium 
pyrophosphate  or  hydroxy  apatite  followed  by  an  inflammatory  response  and 
connective  tissue  degradation,  which  allows  transepidermal  elimination  of, 
degraded dermal deposits.44, 45
• Dysregulation of Vitamin A or Vitamin D metabolism.
• Abnormality of collagen or elastic fibres.
• Diabetic microangiopathy
i. Kyrle’s disease:
It has been widely reported to occur in chronic renal failure. Josef Kyrle first reported it 
in 1916 and called it hyperkeratosis follicularis et parafollicularis in cutem penetrans.46 It 
has  a  tendency  to  affect  blacks  and  it  has  overwhelming  coincidence  with  diabetes 
mellitus and chronic renal failure. 
Clinical criteria 46 described by Kyrle are 
• Chronic  generalized  papular  eruption  of  size  2-8  mm  in  diameter  with 
hyperkeratotic cone shaped plugs present over extensor aspect of extremities.
• Asymptomatic or itchy follicular or extra-follicular lesions.
• Hyperkeratotic verrucous plaques.
• Do not involve mucous membrane, palmar or plantar surfaces.
Histopathological criteria 47 are
• Keratotic plug fills an epithelial invagination.
• Focal parakeratosis 
• Basophilic cellular debris not staining with elastic tissue stains present within the 
plug.
• Abnormal keratinization of all the epidermal cells including the basal cells is present 
in atleast one region deep to the plug.
There are numerous reports in literature of various studies in which skin lesions 
satisfying the above criteria having occurred in renal failure.46, 48, 49, 50 Thus Kyrle’s disease 
appears to have a definite association with chronic renal failure. 
Treatment: 51
Topical keratolytics 
Topical  and intra-lesional glucocorticoids
Topical Tretnoin
Topical 5-FU
UVB 44, 52
PUVA44, 52
Cryotherapy
Systemic isotretnoin
Control of serum phosphorous level
Rarely cured after renal transplantation 53
ii. Perforating folliculitis:
It  was  in  1968  that  Mehregan  and  Cosky  54 first  reported  perforating  folliculitis  in  25 
patients.
Clinically perforating folliculitis has following features
• Elevated erythematous follicular papules with central plugs of keratinous material over 
the hairy areas of arms, forearms, thighs and legs.
• Usually asymptomatic; may be mildly pruritic.
Histopathological features 55 are
Widely dilated hair follicle plugged by a thick mass of orthokeratotic and parakeratotic 
material.
A curled up hair usually cut across is present.
Follicular  epithelium  is  disrupted  with  areas  of  perforation  usually  above  the  level  of 
sebaceous gland, caused by the hair.
At sites of perforation, dermis shows a focal inflammatory infiltrate containing degenerated 
collagen and degenerated elastic fibres, which have lost their orceinophilic properties 
and stain brightly eosinophilic. However there are no increases in elastic fibres.
Lesions with both clinical  and histopathological criteria have been reported to occur in 
renal failure. 56, 57, 58
iii.  Reactive perforating collagenosis: 55
The acquired form of this inherited disorder clinically characterized by umbilicated 
discrete papules usually over sites of trauma and histologically by cup shaped areas of 
depression with parakeratotic keratin, basophilic collagen and perforation through which 
collagen is extruded has been reported to occur in chronic renal failure.59 The nosological 
relationship  between  reactive  perforating  collagenosis  and  the  acquired  perforating 
dermatosis of renal failure still remain uncertain. 60
Pathogenesis:
• Transepidermal elimination of histochemically altered collagen.55
iv. Elastosis perforans serpiginosa: 61
Anecdotal reports of this condition with renal failure are found.
v. Uremic follicular hyperkeratosis: 62
It,  described  by  Garcio  and  Bravo  et  al,  combines  features  of  Kyrle’s  disease  and 
perforating folliculitis  55 occurs quite commonly in patients with renal failure and patients on 
dialysis.
Clinical features:
 Follicular papules with central keratinous plug, which may coalesce to form verrucous 
plaque present over extensor surfaces of lower extremities.
   
Histopathology:
Resemble perforating folliculitis with the perforation in the infundibular region in small 
lesions and at the base in larger lesions.
Since the distinction between these dermatoses is not clear-cut and there is considerable 
overlap especially in patients with renal failure, it has been proposed to group them under a 
common title of acquired perforating disorder. 63, 64
Treatment:
Topical keratolytics, topical glucocorticloids, topical retinoic acid, topical 5 Fluorouracil, UVB, 
control of serum phosphorus level.
6. Metastatic calcification:
It  is  a  frequent  complication  of  chronic  renal  failure  and occurs  when  the  calcium 
phosphate product exceeds the critical value. Abnormally elevated levels of parathormone 
may trigger deposition of calcium pyrophosphate in the dermis, subcutaneous fat or arterial 
walls. Vascular calcification is very common in patients with long term chronic renal failure 
and  is  seldom  symptomatic.  Rarely,  calcium  deposited  gives  rise  to  important  clinical 
categories of calcinosis cutis and calciphylaxis.
i. Calcinosis cutis: 
It is a term used to describe a group of disorders in which calcium deposits found in the 
skin.65  Virchow initially described it in 1855. Calcinosis cutis is seen in the setting of chronic 
renal failure occurring with hyperparathyroidism.
Pathogenesis:
Multiple  factors  in  calcium  metabolism  are  affected.  Hyperphosphatemia  due  to 
decreased renal clearance occur relatively early. Hypocalcaemia occurs as a direct result of 
their  hyperphosphatemia  and is  worsened by renal  failure  induced vit.D  deficiency.  As  a 
compensatory  measure  excess  parathyroid  hormone  is  produced.  This  augmentation  of 
parathyroid hormone results in an increase in calcium and phosphate mobilization and an 
elevated solubility product and subsequently the formation and precipitation of calcium salts.
Clinical features:
Hard  papules,  nodules  or  plaques,  which  typically  occur  around  large  joints,  may 
produce a chalky discharge. This occurs in sub-acute fashion, without livedo, or ischemic 
pain.
HPE:
Granules and deposits of calcium are seen in the dermis with or without a surrounding 
foreign  body  giant  cell  reaction.  Massive  calcium  deposits  may  be  located  in  the 
subcutaneous tissue. In areas of necrosis, calcium deposition is frequently found within the 
walls of small and medium sized blood vessels. Calcium deposition may be confirmed by Von 
kossa and Alizarin red stains. 
Treatment:
 Medical
a) Dietary measures: Restriction of dietary phosphates and calcium. Consumption of 
ketogenic diet includes free fatty acids, which causes accumulation of keto acids, 
metabolic products of fatty acids resulting in decreased pH and thus preventing 
crystallization. 
b) Magnesium or aluminium antacids may be effective phosphate binders in patients 
with  hyperphosphatemia.  However,  use  in  patients  with  renal  insufficiency  may 
result in magnesium or aluminium toxicity.
c) Probenecid and colchicines
d) Intralesional corticosteroid – anti-inflammatory and antifibroblastic activity.
e) Sodium etidronate  and  diphosphonates  –  reduce  bone  turnover  and  inhibit  the 
growth  of  ectopic  hydroxyapatite  crystals.  On  prolonged  treatment  paradoxical 
hyperphosphatemia may result.
f) Warfarin
g) Calcium channel  blockers  –  diltiazem for  5  years.  It  causes antagonism of  the 
calcium – sodium ion pump.
Surgery: Excision  
Indications: 
i. Pain 
ii. Recurrent infections
iii. Ulcerations
iv. Functional impairment
Complications:
Pain,  paraesthesia,  ulceration,  infection,  cosmetic  disfigurement,  mechanical 
compromise, restricted mobility, vascular occlusion resulting in gangrene.
Prognosis: excellent.
ii. Calciphylaxis:
Synonym: calcific uremic arteriolopathy
It  is  a  highly morbid  syndrome characterized by rapidly progressive calcification of 
small and medium sized blood vessels. Bryant and White first reported it in association with 
uremia in 1898. It is a rare, serious complication of chronic renal failure. 66 The mechanism of 
experimental calciphylaxis in nephrectomised rats was described by Hans Selye, physiologist 
in 1962. 67 He was the first to coin the term calciphylaxis to characterize this enigma.
Pathogenesis:
Factors implicated are 
• Chronic renal failure
• Hypercalcemia
• Hyperphosphatemia
• Elevated calcium – phosphate products 68
• Secondary hyperparathyroidism 69
Selye demonstrated that a series of events might be necessary for the formation of 
calciphylaxis using a rat model. He defined calciphylaxis as a condition of hypersensitivity 
induced  by  a  set  of  “sensitizing  agents”  in  which  calcinosis  occurred  only  in  those 
subsequently  subjected  to  a  group  of  ‘challengers’  and  only  after  a  critical  lag  time. 
Experimental  sensitizing  events  and  agents  included  nephrectomy  and  exposure  to 
parathyroid hormone and vit. D. Substances used as challengers included egg albumin and 
metallic salts. Calciphylaxis was the end result.
HPE:
Calcification within the media of small and medium sized arterioles with external intimal 
hyperplasia and fibrosis. A mixed inflammatory infiltrate frequently occurs. Subcutaneous 
calcium deposits with panniculitis and fat necrosis may sometimes be found. Vascular 
microthrombi are frequently evident.
Clinical features: 
It may present as a violaceous pattern of livedo reticularis found primarily on the trunk 
and extremities which results in extensive cutaneous necrosis. 
Treatment: 70
Medical
 Aggravating  factors  should  be  addressed  and  triggering  factors  should  be 
eliminated.
 Dietary alteration (reduction of  phosphorous rich foods),  non calcium containing 
phosphate binders, reduction of dialysate calcium concentration.
 Prevention  of  superimposed  infections  with  wound  care  and  debridement,of 
gangrenous tissue, antibiotics and hyper baric oxygen and pain management.
Surgical
Total or subtotal parathyroidectomy 71, 72 with auto transplantation
Complications:
Ranges from moderate interference with activity to death.
• Non-healing ulcers and cutaneous gangrene 
• Amputation 
• Sepsis
• GI hemorrhage, infarction, and organ failure
Prognosis: Grave. 70
Mortality rate: 60 – 80% 71 particularly when the trunk is involved.
Causes of death: 
 Sepsis
 Organ failure
Exceptional cases of metastatic soft calcifications presenting as large tongue masses 73 or 
perforating papules 74 have been reported.
7. Purpura 
Purpura, petechiae, ecchymoses are due to mild thrombocytopenia or more marked 
platelet dysfunction and increased vascular fragility 42 or associated poor quality collagen. It is 
partly reversed by dialysis.
8. Gynecomastia:
It is occasionally seen in patients with chronic renal failure of unknown etiology. It is 
thought to be an endocrinological complication of renal failure and dialysis. 75
9. Vascular disorders:
i. Microangiopathy – severe  microangiopathy has been revealed  in  skin  biopsies 
from 75% of patients with chronic renal failure. 76
HPE: 
• Endothelial cell activation and / or necrosis.
• Basement membrane zone thickening
• Reduplication of the basal lamina involving both venules and    arterioles, tend 
to regress after successful renal transplantation.
ii. Skin  necrosis –  proximal  skin  necrosis  and  /  or  peripheral  gangrene  may 
occasionally occur in uremic patients.
Proximal  skin  necrosis  can  involve  the  trunk,  shoulders,  buttocks,  or  thighs.  Lesions 
usually spread rapidly covering large areas and have an ominous prognosis.
Distal skin necrosis of the fingers and toes can lead to digital gangrene, but the disease is 
usually self-limiting.
10. Poor wound healing is due to decreased collagen turnover caused by chronic acidosis.
11. Restless leg syndrome is characterized by burning, painful paraesthesia of the dorsal or 
plantar surface of the feet and it is due to peripheral neuropathy.
B. ORAL MUCOSAL CHANGES:
Jaspers has reviewed oral changes, which occur in uremia.  77 The lesions described 
are 78
• Stomatitis is due to chemical burn caused by ammonia released by bacteria due to the 
increased content in the salivary secretion. The other causes are candidial infection 
and impaired immunity. 78
• Ulcerative stomatitis  can occur anywhere in the mouth
• Hemorrhagic lesions
• Hyperkeratosis occurs in long standing renal failure, due to the effect of toxic chemicals 
in the oral mucosa. 77
C. HAIR ABNORMALITIES: 38
They are
• Loss of hair on forearm and legs
• Diffuse alopecia of scalp 79
• Fine dry and brittle hair
• Trichoclasia and trichorrhexis nodosa
• Hair discolouration
Microscopic  examination  of  hair  in  uremia  shows  hair  in  telogen  phase.  With  scanning 
electron microscope, uremic hair shows irregular diameter, flattening and twisting of its shaft 
and mild cuticular abnormalities.
D. NAIL CHANGES:
It occurs in patients with uremia as well as in those undergoing dialysis. Nail changes 
include 80
i. Half and half nail
ii. Brown nail bed arc
iii. Mee’s lines
iv. Muercke’s lines
v. Terry’s lines
i. Half and half nail:
Synonym: Lindsay’s nails. 81
Bean first described half and half nails in 1963. Although not pathognomonic of 
renal  failure,  they occur  in  15-50 %  114 of  patients  on  dialysis  and  disappear  several 
months after successful renal transplantation. Half and half nails are characterized by a 
dark distal band that occupies 20 – 60% of the nail bed and by a white proximal band. The 
distal dark band may range in color from reddish to brown. Although the condition has 
been observed in toenails, it is more commonly seen in fingernails. 
Causes  80
• deposition of melanin in the nail plate due to stimulation of matrix melanocytes.
• Increase of capillaries and thickening of their walls
• Proximal half of the nail appears white because of edema of the nail bed.
Pigment  is  more visible distally than proximal  because of  looser attachment of  the 
distal  nail  plate  to  the  nail  bed.  The  nail  changes  do  not  correlate  with  serum calcium, 
phosphorus or bicarbonate. 82 It is the most useful onychopathologic indicator of renal failure.
ii. Brown nail bed arc: 83
Described by Stewart and Raffle as a brown arch affecting the distal part of the finger 
nail bed, just proximal to the point of separation of the nail from its bed.
          Cause is due to lipochromes.
iii. Mee’s lines:
Single or multiple transverse white bands.
iv. Muercke’s lines: 
Double white transverse lines that represent an abnormality in the vascular bed of the nail.
v. Terry’s nails
These nail changes are fairly specific to chronic renal failure, but may be encountered 
in patients with chronic liver disease and in healthy individuals. It has been applied to 
nails in which only the distal 20% is normal.
vi. Onychodystrophy:
Nail plate is thick, dull and opaque with a yellowish, whitish or grey color. Rarely, a 
severe onychodystrophy with spontaneous resolution may occur. 84
II. SKIN MANIFESTATIONS DUE TO TREATMENT:
1. Pruritus
The incidence of renal pruritus in patients on long term hemodialysis has been shown 
to be as high as 50 – 90% 85, 34  Some patients complain of pruritus only during or soon 
after dialysis, whereas others report symptomatic exacerbation during the same period. 
Pruritus may also be a sign of inadequate dialysis. 86, 87
2. Xerosis:
Significant xerosis occurs for unknown reasons in 50 – 75% of the dialysis population. 
Studies have shown no difference in the hydration of the stratum corneum or the trans 
epidermal water loss between patients on chronic dialysis and controls. However, simple 
emollient therapy has been shown to improve symptoms of pruritus in patients on chronic 
dialysis, perhaps through rehydration of the stratum corneum. 88
Immuno-histochemical studies have shown neuron-specific enolase, immuno-reactive 
nerve fibres sprouting through the epidermis in dialysis patients, but not in control subjects 
indicating that abnormal pattern of cutaneous innervation may occur in dialysis patients 
which may account for their pruritus. 89
3. Pigmentary changes
Brown diffuse hyper pigmentation is more evident in the areas exposed to sunlight 
found in about 60 – 78% 43  of dialysis patients. The incidence is greater in patients with 
longer duration of dialysis. Rare cases of diffuse bluish gray discoloration 90 of the skin and 
nails referred to as ‘argyria’ have been reported. Acquired hair and skin fairness, 91 a result 
perhaps of a disturbance of phenyl  alanine metabolism, may occasionally be found in 
dialysis patients. A sudden deepening of pigmentation 92 during hemodialysis can develop 
in patients with severe hemolysis.
4. Keratotic pits of palms and soles
5. Chronic  hemodialysis  –  related  porphyria/  pseudoporphyria/  drug  induced bullous 
dermatoses.
In a considerable proportion of the patients with chronic renal failure, skin changes 
resembling porphyria cutanea tarda develop some months to years after the onset of 
maintenance hemodialysis. This can be either 
a. Real porphyria cutanea tarda
b. Secondary porphyria cutanea tarda
c. Porphyria cutanea tarda – like bullous dermatoses
a. Porphyria cutanea tarda: 93, 94 It is seen in minor proportion of patients. Chronic renal 
failure  can  influence  hepatic  porphyrin  synthesis  by  reducing  Uroporphyrinogen 
decarboxylase  activity.  This  deficiency  with  impaired  renal  clearance  of  porphyrins 
leads to an accumulation of porphyrins. Increased plasma levels of uroporphyrin do not 
cross the dialysis membrane. Porphyria cutanea tarda can be diagnosed on the basis 
of increased total porphyrin levels with a predominant of uro I > III and heptocarboxy 
porphyrin III > I and fecal isocoproporphyrin. 95
Treatment: Phlebotomy or chloroquine therapies are not usually advisable or effective 
in patients with chronic renal failure. Erythropoietin has been shown to be an effective 
treatment for porphyria cutanea tarda in chronic renal failure population, either alone or 
in combination with phlebotomy. 96, 97
b. Bullous dermatoses 98 of hemodialysis or pseudoporphyria 
It is a syndrome of cutaneous fragility and blistering. It is seen in higher proportion 
of chronic renal failure patients. It is a bullous disorder clinically and histopathologically 
indistinguishable from porphyria. Gilchrist et al described it in the year 1975 and called it 
“bullous dermatoses of hemodialysis”. Korting in the same year observed several uremic 
patients  with  skin  changes  mimicking  porphyria  cutanea  tarda  and  coined  the  term 
“pseudoporphyria”. It occurs in 1-18% 99 of patients on maintenance hemodialysis. Higher 
female:  male  ratio  is  observed.  It  is  more  often  observed  in  adults.  It  occurs  more 
frequently during the summer. It has been reported both in a patient undergoing peritoneal 
dialysis  100 and  in  a  patient  undergoing  hemodialysis  after  reactivation  of  hepatitis  C 
infection. 101
Clinical features:
Morphology: It usually presents as vesicles/ bullae that resolve in few days. Erosions and 
atrophic  scarring  are  seen.  Sometimes  milia  and  dyspigmentation  are  also  observed. 
Sometimes the bulla may be filled with hemorrhagic fluid. Fragility of the skin is present. 
Pathogenesis:-  Due to  unsatisfactory  renal  function,  plasma porphyrins  are  elevated  of 
which uroporphyrin and heptaporphyrins are the dominant fractions. But alterations in the 
ratio of the uro isomers or the presence of isocoproporphyrin cannot be expected.
- May be due to a non-porphyrin photo sensitizing chemical released by the polyvinyl 
chloride used in the plastic tubing for dialysis.
-  Excess  transfusion  leads  to  iron  overload  which  results  in  the  development  of 
porphyria cutanea tarda.
-  Multiple  transfusions  lead to  hepatitis  C virus  infection,  which  result  in  porphyria 
cutanea tarda.
- Effect of aluminum concentration from the environmental sources result in alteration 
of enzymatic process of heme biosynthesis resulting in overproduction of porphyrins.
HPE:
  Kalman and Keechzes and Malcolm farr 102 in their study showed subepidermal bulla. 
Edema in the dermis with scant perivascular lymphocytic infiltrate seen.
Electron microscopy: 
Thickening of  dermal  venular walls and dermo-epidermal  junction due to replicated 
basal  laminae.  Hypogranulated  mast  cells  and  granulofilamentous  hyaline  masses in  the 
dermal connective tissue that appear to be secreted by adjacent fibroblast.
Direct immuno fluorescence:
Presence of IgG and inconsistent IgA, IgM, fibrin, complement around dermal venules 
with IgG and complement noted at dermo-epidermal junction or bulla floor.
Note: due to usage of erythropoietin and screening for Hepatitis C virus, there is decreased 
occurrence of pseudoporphyria.
c. Drug induced bullous dermatoses: 
This  disorder  caused  by  exposure  to  photosensitizing  drugs.  It  is  clinically  and 
histologically indistinguishable from both porphyria cutanea tarda and hemodialysis – related 
porphyria. Phototoxic bullous eruptions have been reported in uremic patients taking nalidixic 
acid,  nabumetone,  tetracycline,  phenytoin,  high  dose  frusemide  and  flutamide.  103,104  The 
diagnosis is based on a positive H/o photosensitizing drug ingestion. Resolution of bullous 
dermatoses usually occurs after the causative agent is discontinued.
Treatment: discontinuation of photosensitizing drug
avoidance of sunlight and visible light and topical sun block preparation
protection of exposed skin from mechanical trauma
N-acetyl  cysteine,  a glutathione precursor  orally at  a  dose of  70 mg/kg p.o.  Q 4h, 
brings resolution of blistering and fragility after 1-2 months of therapy
topical or systemic antibiotics to combat infection
6. Arteriovenous shunt dermatitis:
About 8% of the patients on chronic hemodialysis suffer from AV shunt dermatitis. 
105
a. Arterio-Venous shunt dermatitis
It is characterized by irritant contact dermatitis from soaps, disinfectants and alcohol used for 
skin cleansing during hemodialysis. This dermatitis is most common in patients with pruritus.
Treatment: 
 Mild topical steroids and substitution of normal saline for skin cleansing before 
hemodialysis.
b. Dermopathy associated with venous hypertension of hand caused by hemodialysis shunt 
is much rare. It is characterized by swelling, induration, hyperpigmentation and even ulcer 
formation  restricted  to  thumb and  index finger.  This  disorder  may be  related  to  peri-
capillary cuffs of fibrin due to venous hypertension. 106
c. Arterial steal syndrome:
It is uncommon but highly morbid complication of the vascular access necessary for 
hemodialysis. Production of an adequate vascular access required the formation of an arterio-
venous cannula either by using native vessels (arterio-venous fistula) or by placing synthetic 
tubing (arterio-venous graft). Vascular access is typically placed in the upper extremities.
Arterial steal syndrome may develop if the inevitable proximal shunts of blood are significant 
enough to cause hand ischemia. Proximal shunting is attributed to the reversal of blood flow 
through  distal  arteries  induced  by  the  low-pressure  system  produced  by  arterio-venous 
connector. 
Symptoms:  pain,  numbness,  pulmonary  ischemia  result  in  digital  gangrene,  peripheral 
neuropathy or cutaneous atrophy
7. Vascular malformations:
Acroangiodermatitis or pseudo kaposis sarcoma 38  is a benign vascular proliferation that 
develops distal to an AV shunt and may resolve following thrombus or surgical ligation of the 
shunt.
 Morphology:  purplish nodules or  papules slowly evolving into scaly crusted violaceous 
patches.
 Histology:  vascular  and  fibroblast  proliferation  in  the  superficial  dermis.  Vascular  slits, 
mitotic figures and extravasated RBCs may be seen.
 It may improve if the shunt or AV fistula is removed.
8. Contact dermatitis:  both allergic and irritant contact dermatitis may occur to dialysis 
tubing, nickel (needles) and topical medicaments. 105
9. Nail changes:
 Half and Half nails
 Splinter haemorrhages 
 Onycholysis
10.Hair changes:
 Alopecia 
 Discoloration of hair
 Fine brittle hair 
 Hair shaft abnormalities
11. Infections: Increased carriage of staphylococcus aureus 105 has been found in patients 
undergoing  peritoneal  dialysis  and  hemodialysis  and  may  predispose  patients  to 
folliculitis, furunculosis or catheter site infections.
12.Premalignant conditions: 
 Multiple actinic keratoses may occur in skin exposed to sun and appear as 
scaly, rough red plaque. 107
 Porokeratosis  –  characterized  by  crater  shaped  keratin  may  develop  on 
the access region for hemodialysis. 108
13.Malignancy:
Basal cell carcinoma is the most common skin cancer in uremia occurring in about 4% 
of maintenance dialysis patients. Painless, non-inflamed smooth, translucent nodule, which 
can show numerous telengiectatic vessels near its surface. Nodules often ulcerate and form a 
crust. It may invade nearby structures such as bones, nerves or brain.
14.            Nephrogenic fibrosing dermopathy 110,111  is a recently described disorder which 
resembles scleromyxedema clinically with normal immunoglobulin and no paraprotein. It 
has been found only in patients with renal disease. Most affected individuals have been on 
hemodialysis and many have re-started dialysis after failure of a renal transplant. It also 
has been described in a few patients with acute renal failure. 
Etiology: unknown.
Clinical features: progressive development of erythematous, sclerotic dermal plaques 
on the arms and legs with sparing of the head and neck. Pruritus is a common feature. 
HPE: resembles that of scleromyxedema, with proliferation of fibroblast in the dermis and 
subcutaneous septae, accompanied by increased dermal and septal collagen and mucin. 
Course: persistent
Treatment: No effective treatment
15.Cutaneous reaction to treatment with recombinant human erythropoietin. A papulous 
skin  reaction  as  well  as  generalized  increased  pruritus  following  2-3  months  of 
treatment.
16.Perforating pseudoxanthoma elasticum 
17.Cutaneous calcinosis in hemodialysis
HISTOPATHOLOGICAL CHANGES OF UREMIA IN SKIN:
They have been studied and they include 112
Epidermal 
• moderately thickened stratum corneum
• reduction of prickle cell layers of pyknotic nuclei
• vacuolated cytoplasm of the epidermal cells
• flattening of dermo epidermal junction
Dermal
• dilatation of the capillaries and lymphatics in mild azotemia
• dermal atrophy and loss of dermal blood vessels and       appendages in advanced 
renal failure
MANAGEMENT OF RENAL FAILURE: 3
Specific  management  of  cutaneous  lesions  is  already  discussed  individually.  The 
management of chronic renal failure falls into 3 distinct parts
 investigations  to  detect  the  underlying  renal  disease  and  to  determine  any 
reversible factors which are exacerbating the uremic state
 measures designed to limit adverse effects of loss of renal function and when 
possible to prevent further renal damage
 in patients with progressive destruction of renal tissue, supportive measures in 
the form of either dialysis or transplant are required.
AIMS OF THE STUDY
1. To study the various cutaneous manifestations and their  incidence in  patients  with 
chronic renal failure.
2. To study the age and sex incidence of the individual cutaneous manifestations.
3. To study the incidence and types of cutaneous infections in chronic renal failure.
4. To study the treatment-related (medical and dialysis) dermatologic manifestations of 
chronic renal failure.
5. To correlate between the skin manifestations of systemic disorders with chronic renal 
failure.
MATERIALS AND METHODS
This  study  was  done  for  2  years  from  December  2003  to  December  2005.  at 
nephrology  ward,  Government  general  hospital,  Chennai,  as  well  as  at  Dermatology 
outpatient department (referral cases).
 During  this  period,  the  patients  were  screened  for  the  evidence  of  cutaneous 
manifestations of chronic renal failure. Of these, 75 patients who had the presence of skin 
manifestations were selected and studied. All the 75 patients were known cases of chronic 
renal failure diagnosed at nephrology department/ medical department who presented with 
various stages of renal failure.
All  patients  were  thoroughly investigated  with  routine  hematologic and biochemical 
investigations. When appropriate, radiographs, USG and renal biopsy were done. All these 
patients were managed with drugs and dialysis according to the severity of renal failure.
A thorough history was taken and general examination was done. The skin, hair, nails, 
mucosa were examined thoroughly for specific lesions of chronic renal failure, skin lesions 
due to the treatment and associated skin lesions.
Selected cases were investigated as follows and treated accordingly
a. Scraping of skin for direct microscopic examination with 10% KOH for evidence of 
superficial mycosis in affected patients
b. Culture of skin scrapings for growth of fungal agents
c. Tzanck smear when indicated in viral infections
d. Pus culture and sensitivity
e. Skin biopsy for HPE in selected cases.
OBSERVATIONS
The number of patients studied with chronic renal failure was 75.
Age incidence:
The age of the patients ranged from 16-70 years with a mean of 36 years.
Sex incidence:
Out of 75 patients, males were 51 and females 24, with Male: Female ratio of 2.1: 1.
TABLE - I
sex no. of patients
studied with crf
incidence
Male 51 68%
Female 24 32%
Total 75
I. INCIDENCE OF SPECIFIC CUTANEOUS MANIFESTATIONS OF CHRONIC 
RENAL FAILURE:
A. SKIN:
1. Pruritus
Out of 75 patients, 39 males and 15 females suffered from pruritus 
(fig 1). The total incidence in both sexes was 72%. 12 of the patients had excoriations due to 
pruritus  (fig.  3b).  4  of  them  developed  prurigo  nodularis  (fig  1b,  fig  1c)  and  another  3 
developed lichen simplex chronicus.
TABLE - II
sex no. of persons 
with pruritus
incidence
%
Male 39 52
Female 15 20
Total 54 72
11 patients showed improvement in pruritus following dialysis, no change in 24, and 
worsened in 19.
SPECIFIC CUTANEOUS MANIFESTATIONS OF UREMIA
PRURITUS
Fig 1a
Pruritus with scratch marks
Fig 1b
Prurigo nodularis over the lower legs
Fig. 1c
Histopathology – Prurigo nodularis showing vertical orientation
of collagen in the papillary dermis & irregular acanthosis in
the epidermis
2. Xerosis / ichthyosis:
34 patients developed dryness of skin (fig 2a); Ichthyosis (fig 2b) was noted in 15 patients, 
and acquired plantar hyperkeratosis in 3 males.
TABLE - III
clinical features no. of patients incidence %
Male Female Male Female
Xerosis 23 11 30.6 14.6
Ichthyosis 8 7 10.6 9.3
Plantar hyperkeratosis 3 0 4 0
Total 34 18 45.3 24
3. Pigmentary alterations:
Among pigmentary alterations 16 had diffuse hyper pigmentation (fig 3b), 12 were pale, 8 
were of yellowish hue (fig. 3a) and 4 had pigmented macules over palms (fig. 3c) and soles 
(fig. 3d). The total number of patients with pigmentary alterations was 40. The incidence was 
found to be 53.3%.
XEROSIS
Fig 2a
Dryness of skin over the back
Fig 2b
 Icthyosis over the lower legs
PIGMENTARY CHANGES
Fig 3a
 Sallow yellow discolouration
Fig 3b
Diffuse hyperpigmentation with excoriation marks
Fig 3c
Hyperpigmented macules over the palm
Fig 3d
Hyperpigmented macules over the sole
TABLE - IV
Clinical features No. of patients
male female
Yellow discoloration 3 5
Diffuse hyper pigmentation 11 5
Hypermelanotic macules of palms and soles 2 2
Pallor 7 5
Total 23 17
Incidence % 30.6 22.6
4. Uremic frost: Not noted
5. Perforating  dermatosis:  12  patients  presented  with  the  clinical  morphology  of 
perforating dermatosis. With the help of Histopathological findings, Kyrle’s disease (fig. 
4a, 4b) was seen in 3 patients, perforating folliculitis in 4 (fig 4c, 4d) . Others showed 
features of nodular prurigo and prurigo simplex.
TABLE -V
clinical features no. of patients
Male Female
Kyrle’s disease 1 2
Perforating folliculitis 2 2
Others 2 3
Total number of patients with perforating dermatosis was 7, and the incidence was found 
to be 9.3%.
PERFORATING DISORDERS
Fig 4a
Kyrle’s disease over the upper extremity
Fig 4b
Histopathology of Kyrle’s disease showing basophilic debris in an epidermal invagination. Plug is in 
direct contact with the dermis.
Fig 4c
Perforating folliculitis over the lower leg
Fig 4d
Histopathology of peforating folliculitis with perforation of the follicular epithelium and degenerative 
collagen fibres extruding through the dermis.
Fig 4e
Histopathology of perforating folliculitis – trichrome stain showing elimination of collagen fibres 
through the follicular wall
Fig 5
Purpura over the thighs
6. Metastatic calcification: not noted.
7. Purpura (fig. 5) : over legs were noted in 9 patients. In male patients, the reason was 
mainly due to underlying thrombocytopenia. But in females, 3 were diagnosed to have 
Henoch-Schonlein purpura; one had cryoglobulinemia and another had ITP.
TABLE - VI
Sex No. of patients
with purpura
Incidence
%
Male 3 4
Female 6 8
Total 9 12
8. Gynaecomastia – Not noted 
9. Vascular  disorders:  Digital  gangrene  (fig.  6)  present  over  fingers  was  noted  in  2 
patients.
10.Poor wound healing (fig. 7) : following trauma was seen in 4 patients.
11.  Restless leg syndrome: Two patients had burning pain over the soles of the feet.
Fig 6
Gangrene over the little finger
Fig 7
Poor wound healing in a chronic leg ulcer following trauma
B. MUCOSAL CHANGES:
Stomatitis (fig. 8) was noted in 12 patients. 3 of them had oral ulcers (fig. 9), 2 had 
leukokeratosis of oral mucosa. The total number of patients with mucosal changes was 17, 
and the incidence was found to be 22.6
TABLE -VII
clinical features no. of patients
Male Female
Stomatitis 8 4
Oral ulcers 1 2
Leukokeratosis of oral mucosa 1 1
Total 10 7
Incidence 13.3 9.3
C.  HAIR ABNORMALITIES:  14 had sparse hair  (fig. 10) and 8 had brittle hair.  The total 
number of patients with hair abnormalities was 22. The incidence was found to be 29.3%.
TABLE - VIII
clinical features no. of patients
Male Female
Diffuse alopecia 6 8
Brittle hair 4 4
Total 10 12
Incidence 13.3 16
MUCOSAL CHANGES
Fig 8
Showing stomatitis
Fig 9
Shows ulcer over the labial mucosa and tongue
HAIR ABNORMALITIES
Fig 10 
Shows diffuse loss of hair
D.  NAIL CHANGES: Among 75 patients, 18 had ‘half and half nails’ (fig. 11 & 12), 8 had 
brown nail bed arc (fig. 13). Other nail features such as Mee’s lines and Muercke’s lines were 
not  noted.  4  had  shiny  nails  (fig.  14)  ,  probably  secondary  to  scratching,  3  had 
onychodystrophy (fig. 15)  (nail scraping was done and examined under 10% KOH and found 
to be negative),  2 had melanonychia (fig.16) and one patient had blue nails (fig. 17),  not 
associated with Raynaud’s phenomenon or cyanosis
TABLE – XI
clinical features no. of patients
Male Female
Half and half nail 12 6
Brown nail bed arc 5 3
Shiny nails 1 3
Onychodystrophy & onycholysis 4 1
Melanonychia 2 0
Blue nails 1 0
Total 25 13
Incidence % 33.3 17.3
NAIL CHANGES
Fig 11 
Half and half nails in finger nails
Fig 12 
Half and half nails in toe nails
Fig 13 
Brown nail bed arc in finger nails
Fig 14 
Shiny nails due to scratching
Fig 15
Onychodystrophy of toe nails
Fig 16
Longitudinal melanonychia over the finger nails
Fig 17
Blue nails seen over the fingers, most evident over the thumbs
SPECIFIC CUTANEOUS MANIFESTATIONS OF CRF
TABLE - X
s.no SPECIFIC CUTANEOUS
 MANIFESTATIONS 
NO. OF PATIENTS
Male Female
TOTAL INCIDENCE
%
A SKIN CHANGES
1.1 Pruritus 39 15 54 72
2. Xerosis/ ichthyosis 34 18 52 69.3
3. Pigmentary alterations 23 17 40 53.3
4. Uremic frost 0 0 0 0
5. Perforating disorder 3 4 7 9.3
6. Metastatic calcification 0 0 0 0
7. Purpura 3 6 9 12
8. gynaecomastia
9. Vascular disorders 1 1 2 2.6
1 Poor wound healing 3 1 4 5.3
11.
Restless leg syndrome 1 1 2 2.6
B MUCOSAL CHANGES 10 7 17 22.6
C HAIR ABNORMALITIES 10 12 22 29.3
D NAIL ABNORMALITIES 25 13 38 50.6
II. INCIDENCE OF SKIN MANIFESTATIONS
DUE TO TREATMENT
     (MEDICAL AND DIALYSIS):
Apart from pruritus, pigmentary alterations nail and hair changes, keratotic pit of palms 
(fig.  18a)  noted in  3 patients.  Arteriovenous shunt  dermatitis  was noted in a  patient  and 
eczema around cannula site was noted in 2 patients (fig. 18b).
TABLE XI
sex bullous dermatosis keratotic pits of 
palms 
av shunt 
dermatitis
Male 0 3 0
Female 0 0 1
Total 0 3 1
Incidence 0 4 1.3
CUTANEOUS MANIFESTATIONS DUE TO TREATMENT
(MEDICAL AND DIALYSIS)
Fig 18a
Keratotic pits over the palm
Fig 18b
Eczema around the IJV cannulation site
III. INCIDENCE OF CUTANEOUS INFECTIONS NOTED IN CRF:
BACTERIAL INFECTIONS:
Furunculosis (fig. 19) was seen in 3 patients and infected leg ulcers in 2 patients. Pus culture 
revealed staphylococcal aureus in 2 patients. 
VIRAL INFECTIONS:
Herpes simplex labialis was seen in 3 patients.  One patient  had herpes zoster (fig 20a), 
Tzanck smear revealed multinucleated giant cells (fig. 20b). Verruca vulgaris was noted in 4 
patients. Palmar (fig. 20 c) wart was seen in 1 patient.
FUNGAL INFECTIONS:
Pityriasis versicolor (fig. 21a) was seen in 6 patients. Among dermatophyte infections, 4 had 
tinea cruris, 2 had tinea corporis (fig. 21b) and 1 with extensive dermatophytosis. Scraping for 
direct microscopic visualization of fungal elements with 10% KOH was done and found to be 
positive for all cases. Culture was positive in one case. The organism grown in culture was 
Trichophyton  rubrum.  Oral  candidiasis  (fig.  21c)  was  noted  in  2  patients.  Vulvovaginal 
candidiasis was seen in 2 patients. 
PARASITIC INFESTATIONS:
Scabies (fig. 22) was seen in 2 patients. 
Total number of patients with cutaneous infections and infestations were found to be 33, and 
the incidence was 43.8 %. 
CUTANEOUS INFECTIONS IN CRF
TABLE - XII
cutaneous infections no. of 
patients
total incidence
Bacterial 
infections
Furunculosis 3
Infected leg
ulcers
2
5 6.6
Viral 
infections
HS labialis 3
Herpes zoster 1
Verruca vulgaris 4
Plane wart 1
9 12
Fungal 
infections
Pityriasis versicolor 6
Dermatophytosis 7
Oral candidiasis 2
Candidial vulvovaginitis 2
17 22.6
Parasitic 
infestations
Scabies 2 2 2.6
Total                       33 43.8
CUTANEOUS INFECTIONS AND INFESTATIONS IN CRF
BACTERIAL INFECTION
Fig 19
Furuncle present over the thigh
VIRAL INFECTIONS
Fig 20a
Herpes zoster – T1 dermatome
Fig 20b
Multinucleated giant cells seen in the above patient
Fig 20c
Shows palmar wart
FUNGAL INFECTIONS
Fig 21a
Pityriasis versicolor over the chest
Fig 21b
Showing Tinea corporis
Fig 21c
Oral candidiasis seen over the tongue
PARASITIC INFESTATIONS
Fig 22
Showing scabies
IV. INCIDENCE OF ASSOCIATED SKIN LESIONS:
These were classified into 
1. Skin lesions contributing to the etiology of CRF
Skin  changes  of  diabetes  mellitus  like  acanthosis  nigricans,  perforating  folliculitis, 
peripheral  neuropathy  were  noted  in  10  patients.  Skin  changes  of  systemic  lupus 
erythematous (fig. 23) like malar rash, erythematous scaly plaques, discoid rash and diffuse 
alopecia of the scalp were noted in 3 patients. Cutaneous findings of scleroderma like hide-
bound skin, sclerodactyly salt and pepper pigmentation (fig. 24), and pitted scars were noted 
in 2 patients.  2 patients presented with vasculitic  ulcer on (fig.  25) lower legs. 5 patients 
presented with  purpura that had differing etiologies like ITP,  cryoglobulinemia,  HSP. One 
case of Ellis van creveld syndrome (fig. 26) with cortical medullary disease presented with 
cutaneous changes. One case of tuberous sclerosis with renal involvement presented with 
cutaneous changes like angiofibroma (fig. 27), shagreen patch, ashleaf macules.
SKIN CHANGES CONTRIBUTED TO ETIOLOGY OF CRF
TABLE – XIII A
diseases no. of patients
Male Female
total incidence
%
Diabetes mellitus 6 4 10 13.3
SLE 0 3 3 4
Scleroderma 0 2 2 2.6
Vasculitis 2 0 2 2.6
ITP 0 1 1 1.3
Cryoglobulinemia 0 1 1 1.3
HSP 0 3 3 4
Ellis van creveld 0 1 1 1.3
Tuberous sclerosis 0 1 1 1.3
ASSOCIATED SKIN LESIONS
Fig 23
Systemic lupus erythematosus patient with lupus nephritis
Fig 24
Salt and pepper pigmentation noted in a scleroderma patient
Fig 25
Vasculitic ulcer
Fig 26
Ellis van creveld syndrome with cortical medullary disease
Fig 27
Angiofibroma in tuberous sclerosis patient with renal involvement
Fig 28
Stasis eczema in an uremic patient
2. Skin lesions associated with CRF
Non-specific skin diseases associated with these patients were LP, erythroderma, eczema 
with sensitization, stasis eczema (fig. 28), vitiligo, phrynoderma, bullous pemphigoid (fig. 29), 
pellagroid dermatitis (fig.30)
INCIDENCE OF ASSOCIATED SKIN LESIONS
TABLE – XIII-B
diseases no. of patients
Male Female
total incidence
%
Lichen planus 2 1 3 4
Bullous pemphigoid 1 0 1 1.3
Erythroderma 1 0 1 1.3
Eczema with 
sensitization
1 0 1 1.3
Stasis eczema 3 1 4 5.3
Pellagroid dermatitis 1 0 1 1.3
Vitiligo 2 2 4 5.3
Phrynoderma 3 1 4 5.3
Fig 29
A bullous pemphigoid patient with chronic renal failure
Fig 30
Pellagroid dermatitis in an alcoholic with CRF
DISCUSSION
In this study including 75 patients with CRF, the mean age was around 36 years, which 
is in par with the literature of 30-60 yrs2. There was a male preponderance with male: female 
of 2.1: 1 in this study which goes in par with the literature. 2
I. SPECIFIC CUTANEOUS MANIFESTATIONS OF CRF:
A. SKIN CHANGES:
1. Uremic pruritus was seen in 72% and is between the reported ranges of 50 - 90% 35, 
86 in one study and 40 – 70% 113 in another study. 14.6% of the patients with pruritus improved 
with dialysis, 25.3% worsened after dialysis and 32% had no change, which also is in par with 
the literature where 25% 8  developed pruritus during dialysis and 42% 8  had severe pruritus 
during dialysis. These suggest that dialysis may be a trigger for pruritus. 
2. Xerosis was seen in 34 patients involving both trunk and extremities. Ichthyosis was 
seen in  15 patients,  mostly involving lower  extremities.  All  patients  with  xerosis  also had 
associated pruritus. The incidence of xerosis was found to be 45.2% which lies nearer to the 
literature of 50 – 75% 
3.  Pigmentary  alterations:  Diffuse  pigmentation  over  sun-exposed  areas  which  is 
reported in 60-78%43 of uremic patients was seen only in 21.3% in this study. Pallor of the 
skin was seen in 16%. Sallow grey pigmentation was noted in 8 patients. Hypermelanotic 
macules of the palms and soles were seen in 4 patients, whereas considerable cases have 
been reported in the literature43. The total incidence of patients showing pigmentary changes 
was 53.3%. 
4. Perforating dermatoses: This was seen in 12 patients clinically. Skin biopsies were 
done  for  histopathologic  evaluation.  Using  clinical  and  histopathologic  correlation,  Kyrle’s 
disease was found in 3 patients; Perforating folliculitis in 4 patients and features of nodular 
prurigo and prurigo simplex in other 5 patients. The incidence of perforating disorders in this 
study was 9.3% which lie in the range of 4-10% 63 of patients in the literature. 
5. Purpura: was noted in 7 patients giving an incidence of 9.3%. Mild thrombocytopenia 
or marked platelet dysfunction could have contributed to the occurrence of purpura in some 
patients. Henoch-Schonlein purpura, ITP, cryoglobulinemia as etiologies of CRF presented 
with purpuric lesions over lower legs. 
Interesting findings noted were – digital gangrene was seen in 2 patients, poor wound healing 
following trauma was noted in  4 patients  and restless leg syndrome was diagnosed in  2 
patients.
B. MUCOSAL ABNORMALITIES:
Oral  mucosal  lesions  were  seen  in  17  patients  with  incidence  of  22.6%.  Uremic 
stomatitis was the commonest mucosal change seen in 12 patients with severe end stage 
renal disease. Oral ulcers over the buccal mucosa were seen in 3 patients. Leukokeratosis 
was  seen  as  whitish  plaques  in  the  oral  mucosa  noted  in  2  patients.  Except  for  the 
hemorrhagic lesions, all the other oral mucosal changes were seen in this study.
C. HAIR ABNORMALITIES:
About 18.6% of the patients reported diffuse loss of hair resulting in sparse hair. Brittle 
dry hair was seen in 8 patients in this study. 
D. NAIL CHANGES:
Half and half nails reported to occur in 15-50% 114 of uremic patients were seen in 24% 
of patients in this study. Brown nail bed arcs were seen in 10.6% as compared to 35%83 in 
one study. Thus the incidence of specific nail changes was comparatively lower in this study 
except for half and half nail.  Other changes noted are shiny nails, probably due to scratching, 
melanonychia,  onycholysis,  onychodystrophy.  Blue  nails  were  seen  in  a  patient  during 
hemodialysis. 90 This was a rare finding reported in the literature. Mee’s and Muercke’s lines 
were not seen. 
Specific  lesions not noted during this study were bullous lesions, uremic frost,  and 
metastatic calcification.
II. SKIN CHANGES DUE TO TREATMENT
(MEDICAL AND DIALYSIS):
Arteriovenous shunt dermatitis was noted in 1.3 % only, low compared to the literature 
of 8% 105. The low incidence may be due to proper wound care and good antibiotic coverage. 
Eczema  around  cannula  site  was  noted  in  2  patients.  Dialysis  induced  pruritus  and 
pigmentary alterations were seen in small percentage of the patients. Keratotic pits of palms 
were noted in three patients, which have been reported considerably in few studies43,38. Drug 
induced  bullous  dermatosis,  pseudo  porphyria,  pseudo  Kaposi’s  sarcoma;  vascular 
malformations were not seen in this study.
III. CUTANEOUS INFECTIONS IN CRF:
Fungal infections were found to be most common in this study.  Dermatophytosis and 
pityriasis versicolor were the two common superficial mycoses. Extensive dermatophytosis 
was seen in one patient. Oral candidiasis was noted in 2 patients. Candidial vulvovaginitis 
was noted in 2 patients of which one was associated with diabetes mellitus. 
Viral  infections  were  the  next  highest  in  incidence,  with  verruca  vulgaris  found  in 
significant number of patients. Herpes simplex labialis and Herpes zoster were reported in 
association with severe pain. 
Bacterial  infections were low in  incidence.  This  may be due to  adequate antibiotic 
coverage in the ward. Staphylococcus aureus was grown in culture. 
Classical scabies was seen in 2 patients.
The  increased  incidence  of  cutaneous  infections  of  43.8%  could  be  due  to  an 
increased susceptibility to infections as a result of impaired immunity seen in uremia. There 
was no case of immunosuppression-induced tumors noted during the study. 
IV. ASSOCIATED SKIN LESIONS:
Certain skin changes helped in identifying the etiological causes of renal failure in this 
study.  Skin  lesions  of  systemic lupus erythematosus like  malar  rash,  erythematous scaly 
plaques,  atrophic  depigmented  plaques,  diffuse  alopecia  were  seen  in  3  patients. 
Characteristic facies with pinched up nose, small mouth, sclerodactyly and salt and pepper 
pigmentation, hide-bound skin with digital pitted scars were noted in 2 patients. All of them 
had renal involvement and the cutaneous manifestations provided clue to the etiology of renal 
failure.  Skin  lesions  of  diabetes  mellitus  showing acanthosis  nigricans,  and vulvovaginitis 
were seen in 10 patients. Vasculitic ulcers were noted in 2 patients. Purpura was noted as a 
clinical  manifestation  occurring  in  proven  cases  of  Idiopathic  thrombocytopenic  purpura, 
Henoch shonlein purpura and cryoglobulinemia. Ellis van creveld syndrome with renal finding 
of cortical medullary disease presented as end stage renal disease. 
Other associated skin lesions were lichen planus, which was seen in 3 patients, all of 
them were negative for hepatiris C virus infection indicating no etiological relationship in the 
particular patients; erythroderma in one patient, eczema with sensitization in one patient and 
stasis eczema in 4 patients. Pellagroid dermatitis was noted in an alcoholic patient. Vitiligo 
and phrynoderma were noted in 4 patients each. Bullous pemphigoid was seen in a patient 
without any associated history of drug intake such as frusesmide. 
CONCLUSION
This clinical study of cutaneous manifestations of chronic renal failure was done during 
the period December ’03 to December ‘05 revealed the following
1. Most of the specific cutaneous manifestations of chronic renal failure were seen in this 
study.  Pruritus  and  xerosis  were  the  most  common  among  the  specific  cutaneous 
manifestations of chronic renal failure. Pigmentary alterations and nail abnormalities were 
the next. Mucosal and hair abnormalities were noted in good percentage of cases. Nearly 
10% had perforating dermatosis and purpura. Interesting findings noted in this study were 
digital gangrene, poor wound healing, and restless leg syndrome. 
2. Skin changes due to treatment reported were arteriovenous shunt dermatitis, keratotic pits 
of palms in small percentage and blue nails in a patient during hemodialysis, other than 
pruritus and pigmentary alterations. 
3. Cutaneous  infections  and  infestations  were  seen  in  43.8  %  of  the  cases.  This  high 
incidence  could  be  due  to  impaired  immunity  resulting  in  increased  susceptibility  to 
infections  in  chronic  renal  failure  patients.  Fungal  infections  were  the  most  common, 
followed by viral, bacterial and parasitic infestations.
4. Associated  skin  changes  of  systemic  diseases  helped  in  finding  varying  etiologies  of 
chronic renal failure such s diabetes mellitus, systemic lupus erythematosus, scleroderma, 
vasculitis,  Henoch  schonlein  purpura,  idiopathic  thrombocytopenic  purpura.  A  case  of 
cortical  medullary disease in Ellis  van creveld syndrome was reported with  cutaneous 
changes. A case of tuberous sclerosis with renal involvement and skin changes was seen. 
Other associated skin changes were not related to the etiology and were found to be just 
coincidental. 
PROFORMA
A CLINICAL STUDY OF THE  
CUTANEOUS MANIFESTATIONS OF CHRONIC RENAL 
FAILURE
1. NAME:
2. AGE / SEX:
3. ADDRESS:
4. WARD No.:
5. EVALUATION OF RENAL FAILURE:
a) Etiology
b) Duration
6. TREATMENT FOR RENAL FAILURE:
a) Drugs
b) Dialysis
c) Duration
7. COMPLAINTS REGARDING SKIN MANIFESTATIONS:
COMPLAINTS DURATION SITE
a) Pruritus
b) Pigmentation
c) Purpuric spots
d) Hair changes
e) Nail changes
f) Poor wound healing
g) Any other skin changes
8. GENERAL EXAMINATION:
a) anaemia
b) edema
c) hydration
d) pulse rate
e) BP
f) CVS
g) RS
h) P/A
i) CNS
j) Fundoscopy
k) P/R in male
l) P/V in female
9. DERMATOLOGICAL EXAMINATION:
a) cutaneous manifestations specific for renal failure
i) skin changes
1. Pruritus
2. Pigmentary disturbances
3. Xerosis / Ichthyosis
4. Perforating dermatosis
5. Purpura, ecchymoses, haematoma
6. Metastatic calcification – calcinosis cutis, calciphylaxis
7. Uremic frost
8. Poor wound healing
9. Gynecomastia
10.Scratch marks
ii) oral mucosal changes
iii) nail changes
iv) hair changes
b) cutaneous manifestations due to treatment
Due to dialysis
1. Pruritus
2. Bullous dermatoses
3. Vascular malformations
4. AV shunt dermatitis
5. Nail changes
6. Hair changes
7. Keratinization disorder
8. Neoplasms
10. INVESTIGATIONS
a) Renal
1. urine analysis
2. urine culture
3. blood Hb%
4. blood TC
 DC
 ESR
5. platelet count
6. blood – urea
- sugar
7. serum – creatinine
- electrolytes
- alk. Phosphotase
8. USG abdomen
9. duplex Doppler scan of renal arteries
10.MR angiography
11.renal biopsy
b) Skin
1. skin biopsy
2. tzanck smear
3. scraping for fungus – 10% KOH  
– Culture
–
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MASTER CHART
Sl.
no
case no. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Age         20 35 30 17 21 41 45 50 32 30 35 50 24 49 46 55 26 29 16
Sex M M F M M F M M F M F M F M M M M F M
Duration ( in years) 1 2 2 1 3 3 5 2 2 3 1 1 2 3 2 3 2 4 1
III Cutaneous infections and 
infestations
Fungal infections + + + +
Viral infections + + +
Bacterial infections +
Parasitic infestations
IV Associated skin lesions
Contributing etiology of  
CRF
Diabetes mellitus + + +
Systemic lupus erythematosus +
Scleroderma
Vasculitis + +
ITP, Cryoglobulinemia
Henoch Schonlein Purpura + +
Ellis Van Creveld syndrome
Tuberous sclerosis +
Other associated skin lesions
Bullous pemphigoid
Lichen planus
+ + + +
Sl.
no
case no. 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39
Age         19 25 43 47 40 39 50 22 36 40 42 41 42 51 24 70 38 35 22
Sex M F M M M M M F M M M M M M F M M F M
Duration ( in years) 2 7 2 2 3 2 2 1 3 5 3 3 2 3 1 4 2 3 3
Specific lesions due to CRF
Skin changes
Pruritus + + + + + + + + + + + + +
2a Xerosis + + + + + + + + + +| + +
2b Icthyosis + + +
Pigmentary alterations + + + + + + + + + +
Uremic frost
Sl.
no
case no. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Age         20 35 30 17 21 41 45 50 32 30 35 50 24 49 46 55 26 29 16 52
Sex M M F M M F M M F M F M F M M M M F M M
Duration ( in years) 1 2 2 1 3 3 5 2 2 3 1 1 2 3 2 3 2 4 1 3
I Specific lesions due to 
CRF
A Skin changes
1 Pruritus + + + + + + + + + + + + +
2a Xerosis + + + + + + + + + + + +
2b Icthyosis + + + + + +
3 Pigmentary alterations + + + + + + + + + + + + + + +
4 Uremic frost
5 Perforating dermatoses + +
6 Metastatic calcification
7 Purpura + + + + +
8 Gynaecomastia
9 Vascular disorders
10 Poor wound healing
11 Restless leg syndrome +
B Mucosal changes + + + + + +
C Hair abnormalities + + + + + + + +
D Nail abnormalities + + + + + + + + + + + + + +
II Skin changes due to 
treatment
1 Pseudoporphyria
2 Vascular malformations
3 AV shunt dermatitis
4 Keratotic pits of palms +
Perforating dermatoses + +
Metastatic calcification
Purpura + +
Gynaecomastia
Vascular disorders +
10 Poor wound healing +
11 Restless leg syndrome
Mucosal changes + + + + +
Hair abnormalities + + + + + + +
Nail abnormalities + + + + + + + + + + +
Skin changes due to 
treatment
Pseudoporphyria
Vascular malformations
AV shunt dermatitis
Keratotic pits of palms
Sl.
no
case no. 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39
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Sex M F M M M M M F M M M M M M F M M F M
Duration ( in years) 2 7 2 2 3 2 2 1 3 5 3 3 2 3 1 4 2 3 3
III Cutaneous infections and 
infestations
Fungal infections + + + + + +
Viral infections + + + +
Bacterial infections +
Parasitic infestations +
IV Associated skin lesions
Contributing etiology of  
CRF
Diabetes mellitus + + +
Systemic lupus erythematosus +
Scleroderma
Vasculitis
ITP, Cryoglobulinemia + +
Henoch Schonlein Purpura
Ellis Van Creveld syndrome
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Other associated skin lesions
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Lichen planus +
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Specific lesions due to CRF
Skin changes
Pruritus + + + + + + + + + + + + +
2a Xerosis + + + + +
2b Icthyosis +
Pigmentary alterations + + + + + + + + + +
Uremic frost
Perforating dermatoses +
Metastatic calcification
Purpura + + +
Gynaecomastia
Vascular disorders
10 Poor wound healing +
11 Restless leg syndrome +
Mucosal changes + +
Hair abnormalities + + + +
Nail abnormalities + + + + + + +
Skin changes due to 
treatment
Pseudoporphyria
Vascular malformations
AV shunt dermatitis +
Keratotic pits of palms + +
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no
case no. 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59
Age         23 19 68 43 41 45 24 50 25 40 18 24 19 47 27 31 24 28 40
Sex F F M M M M F M M M M M F M M M M F F
Duration ( in years) 2 1 3 2 4 2 2 2 3 2 2 3 3 2 6 1 2 2 3
III Cutaneous infections and 
infestations
Fungal infections + + + + +
Viral infections + + + +
Bacterial infections +
Parasitic infestations
IV Associated skin lesions
Contributing etiology of  
CRF
Diabetes mellitus +
Systemic lupus erythematosus
Scleroderma +
Vasculitis
ITP, Cryoglobulinemia
Henoch Schonlein Purpura +
Ellis Van Creveld syndrome
Tuberous sclerosis
Other associated skin lesions
Bullous pemphigoid +
Lichen planus +
Sl.
no
case no. 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75
Age         50 18 65 48 47 29 34 39 28 43 23 26 28 41 25
Sex M F M M F F F M M M F M F F M
Duration ( in years) 8 1 4 3 1 2 7 3 2 2 2 1 3 2 2
I Specific lesions due to CRF
A Skin changes
1 Pruritus + + + + + + + + + + + + +
2a Xerosis + + + + + + +
2b Icthyosis + + +
3 Pigmentary alterations + + + + +
4 Uremic frost
5 Perforating dermatoses +
6 Metastatic calcification
7 Purpura +
8 Gynaecomastia
9 Vascular disorders +
10 Poor wound healing +
11 Restless leg syndrome
B Mucosal changes + + + +
C Hair abnormalities + + +
D Nail abnormalities + + + + +
II Skin changes due to 
treatment
1 Pseudoporphyria
2 Vascular malformations
3 AV shunt dermatitis
4 Keratotic pits of palms
Sl.
no
case no. 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75
Age         20 35 30 17 21 41 45 50 32 30 35 50 24 49 46
Sex M M F M M F M M F M F M F M M
Duration ( in years) 1 2 2 1 3 3 5 2 2 3 1 1 2 3 2
III Cutaneous infections and 
infestations
1 Fungal infections +
2 Viral infections + +
3 Bacterial infections
4 Parasitic infestations +
IV Associated skin lesions
A Contributing etiology of  
CRF
1 Diabetes mellitus + + +
2 Systemic lupus erythematosus
3 Scleroderma +
4 Vasculitis
5 ITP, Cryoglobulinemia
6 Henoch Schonlein Purpura
7 Ellis Van Creveld syndrome
8 Tuberous sclerosis
B Other associated skin lesions
1 Bullous pemphigoid
2 Lichen planus
